Simcere Pharmaceutical Group, commonly known as Simcere, is a leading pharmaceutical company based in Nanjing, China. Founded in 1995, Simcere has become a prominent player in China's pharmaceutical industry, offering a wide range of medications and healthcare products. Simcere's headquarters is located in the Jiangning Development Zone in Nanjing.

This state-of-the-art facility serves as the company's administrative center and houses various research and development departments. The headquarters also boasts advanced production and testing facilities, ensuring the highest quality standards for their products. Simcere's main products include prescription drugs, over-the-counter medication, and healthcare products.

The company has built a diverse portfolio encompassing therapeutic areas such as oncology, cardiovascular diseases, infectious diseases, and gastroenterology. Noteworthy products include Endu, a blockbuster oncology drug, and Bicun, an antiviral medication. On a global scale, Simcere has expanded its reach through joint ventures and partnerships.

In 2014, the company entered into a strategic collaboration with Bristol-Myers Squibb, a multinational pharmaceutical company. Through this partnership, Simcere gained exclusive rights to distribute certain Bristol-Myers Squibb products in China. Simcere also maintains close ties with other international pharmaceutical companies, enabling the exchange of knowledge and expertise.

Simcere holds a strong market position in China, ranking among the top pharmaceutical companies in the country. Its global sales have steadily increased over the years, fueled by a focus on innovation and quality. The company's commitment to research and development has led to significant achievements, including the successful launch of new drugs and the acquisition of patents.

In recent years, Simcere has undergone several key events and changes that have shaped its growth and strategy. The establishment of strategic partnerships, research collaborations, and the acquisition of new drugs have allowed the company to expand its product pipeline and strengthen its market position. Currently, Simcere continues to thrive as a leading pharmaceutical company in China.

It remains committed to research and development, aiming to bring innovative and high-quality medicines to patients worldwide. With its focus on global partnerships and a strong track record of success, Simcere is well-positioned to continue its growth in the pharmaceutical industry